Can-Fite BioPharma annual shares outstanding
2019
2020
2021
2022
2023
2024
2025
Can-Fite BioPharma Shares Outstanding History (CANF)
Can-Fite BioPharma reported 2.6M shares outstanding at the end of fiscal 2025.
View full Can-Fite BioPharma company overviewCan-Fite BioPharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.6M | 1.6M | +163.32% |
| 2024 | 2024-12-31 | 994,394 | −1.36B | −99.93% |
| 2023 | 2023-12-31 | 1.36B | 544.1M | +66.70% |
| 2022 | 2022-12-31 | 815.7M | 0 | 0.00% |
| 2021 | 2021-12-31 | 815.7M | 352.0M | +75.89% |
| 2020 | 2020-12-31 | 463.8M | 343.1M | +284.38% |
| 2019 | 2019-12-31 | 120.7M | — | — |
Can-Fite BioPharma quarterly shares outstanding
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 2.6M | −1.36B | −99.81% |
| Q2 2025 | 2025-06-30 | 3.97B | 2.74B | +223.91% |
| Q4 2024 | 2024-12-31 | 994,394 | −814.8M | −99.88% |
| Q2 2024 | 2024-06-30 | 1.67B | 856.0M | +104.93% |
| Q4 2023 | 2023-12-31 | 1.36B | 544.1M | +66.70% |
| Q2 2023 | 2023-06-30 | 1.22B | 709.1M | +137.49% |
| Q4 2022 | 2022-12-31 | 815.7M | 352.0M | +75.89% |
| Q2 2022 | 2022-06-30 | 815.7M | 404.5M | +98.36% |
| Q4 2021 | 2021-12-31 | 815.7M | 695.1M | +576.11% |
| Q2 2021 | 2021-06-30 | 515.7M | — | — |
| Q4 2020 | 2020-12-31 | 463.8M | — | — |
| Q2 2020 | 2020-06-30 | 411.3M | — | — |
| Q4 2019 | 2019-12-31 | 120.7M | — | — |
Can-Fite BioPharma shares outstanding trends
Over the last five reported fiscal years, Can-Fite BioPharma's shares outstanding moved from 463.8M to 2.6M, a change of −461.2M. The latest reported quarter, Q4 2025, shows 2.6M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Can-Fite BioPharma filings at SEC.gov ↗